| Bioactivity | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia[1][2]. |
| Target | TFPI. |
| Invitro | Concizumab 以浓度依赖性方式增加凝血酶峰值[1]。 |
| In Vivo | Concizumab (i.v./s.c.) 阻断 TFPI 与食蟹猴中 FXa 活性位点的相互作用[2]。 Animal Model: |
| Name | Concizumab |
| CAS | 1312299-39-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696. [2]. Agersø H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9. |